| domain | disease-specific finding | suggested ontology terms/IDs where confidently known | evidence type | caveat |
|---|---|---|---|---|
| Disease identity | Holoprosencephaly 12 with or without pancreatic agenesis is a Mendelian syndrome associated with recurrent heterozygous de novo **CNOT1** p.Arg535Cys and characterized by HPE in all reported syndrome cases, often with pancreatic agenesis/insufficiency (pqac-00000001, pqac-00000002, pqac-00000003, pqac-00000004) | MONDO: **MONDO_0032787**; gene: **CNOT1** | Human case reports/series; curated disease-target association | Open Targets links MONDO_0032787 most strongly to **CNOT1**; older literature and some databases may still mention other HPE genes in broader differential |
| Causal variant | Reported syndrome-defining variant is **CNOT1 c.1603C>T, p.(Arg535Cys)**, heterozygous and de novo in reported families/cases (pqac-00000002, pqac-00000003) | HGVS: **c.1603C>T**, **p.Arg535Cys** | Human WES + parental confirmation | Current disease entity appears driven by this specific recurrent missense variant rather than generic CNOT1 haploinsufficiency |
| Inheritance | Observed inheritance in reported cases is **autosomal dominant, de novo** (pqac-00000002, pqac-00000003) | inheritance term label: autosomal dominant; de novo | Human trio sequencing | Penetrance outside reported Arg535Cys cases is unknown for this syndrome definition |
| Brain phenotype | HPE present in all reported syndrome cases; semilobar and lobar forms have both been described, including fetal semilobar HPE with severe midline defects (pqac-00000002, pqac-00000003, pqac-00000004) | HPO labels: holoprosencephaly; semilobar holoprosencephaly; lobar holoprosencephaly | Human fetal/postnatal phenotyping, imaging, autopsy | Exact HPO IDs not confirmed here; severity is variable across reported individuals |
| Pancreas phenotype | Pancreatic anomalies occurred in **5/6** reported Arg535Cys cases; **pancreatic agenesis** documented in **4/6** and pancreatic endocrine/exocrine insufficiency in others (pqac-00000003, pqac-00000004) | HPO labels: pancreatic agenesis; exocrine pancreatic insufficiency; diabetes mellitus | Human case series, autopsy | Small sample size; one reported case lacked pancreatic anomaly |
| Endocrine phenotype | Pancreatic endocrine failure may present as **neonatal diabetes** in pancreas agenesis; a newer 2024 report indicates **late-onset diabetes mellitus** can also occur with CNOT1 p.Arg535Cys (pqac-00000003, pqac-00000004, pqac-00000000) | HPO labels: neonatal diabetes mellitus; diabetes mellitus | Human case reports; review citing newer case | The late-onset diabetes primary report was not directly extracted here; treat as recent extension of phenotype pending full-text confirmation |
| Exocrine phenotype | Exocrine pancreatic insufficiency is part of the reported spectrum and may occur with or without complete agenesis (pqac-00000003, pqac-00000004) | HPO label: exocrine pancreatic insufficiency | Human case series | Frequency is imprecise because some reports summarize insufficiency and agenesis together |
| Growth/fetal phenotype | **Intrauterine growth restriction (IUGR)** was reported in **4/6** syndrome cases; broader pancreas agenesis literature shows severe fetal growth restriction, especially after 36 weeks (pqac-00000004, pqac-00000006) | HPO label: intrauterine growth restriction | Human case series; semiquantitative literature analysis | Growth restriction data in van Poppel 2024 are for pancreas agenesis broadly, not exclusively CNOT1-associated disease |
| Craniofacial phenotype | Recurrent dysmorphology includes median/large facial cleft, cleft lip/palate, hypertelorism, low-set/posteriorly rotated ears, epicanthal folds, nasal bridge anomalies, microcephaly, and related midline craniofacial defects (pqac-00000003, pqac-00000004) | HPO labels: cleft lip; cleft palate; hypertelorism; low-set ears; microcephaly; epicanthal folds | Human fetal autopsy and case summaries | Frequencies per feature are not established due to very small case count |
| Anatomy affected | Primary anatomical structures are the **forebrain/midline brain** and **pancreas**; fetal autopsy also reported **arhinencephaly**, absent corpus callosum, and occasional **gallbladder agenesis** (pqac-00000003, pqac-00000004) | UBERON labels: forebrain, cerebral hemisphere, pancreas, gallbladder; HPO labels: arhinencephaly; agenesis of corpus callosum | Human autopsy/imaging | Some anatomy terms are labels only because exact ontology IDs were not verified here |
| Molecular mechanism | CNOT1 encodes the scaffold of the **CCR4-NOT** complex, a regulator of gene expression, RNA stability, and mRNA deadenylation; syndrome mechanism has been proposed to impair pancreatic and neurologic development, with discussion of abnormal **SHH** pathway regulation in embryogenesis (pqac-00000002, pqac-00000005) | GO labels: mRNA deadenylation; regulation of mRNA stability; gene expression; signaling by Hedgehog | Human genetics; functional studies in related CNOT1 models/reviews | Direct disease-specific mechanistic proof for Arg535Cys remains limited in the extracted evidence; much mechanistic support is inferential or from broader CNOT1/CCR4-NOT biology |
| Broader CNOT1 function | Independent 2020 CNOT1 cohort established that other de novo CNOT1 variants cause neurodevelopmental disorder, supporting dosage-sensitive developmental roles for CNOT1 (pqac-00000005) | gene: CNOT1; pathway label: CCR4-NOT complex | Human cohort; Drosophila functional assays | These variants generally do **not** define HPE12/pancreatic agenesis; they broaden CNOT1 disease biology rather than this exact syndrome |
| Diagnostics | Suggested workflow: prenatal ultrasound may detect severe HPE; fetal MRI refines brain anomalies; diagnosis has been achieved by **whole-exome sequencing** with parental confirmation; fetal autopsy can reveal pancreatic agenesis missed prenatally (pqac-00000003, pqac-00000007) | MAXO/clinical labels: prenatal ultrasound, fetal MRI, whole-exome sequencing, Sanger confirmation, fetal autopsy | Human fetal case report; HPE review | Pancreas visualization prenatally can be limited, especially early gestation |
| Differential molecular testing | In HPE generally, chromosomal analysis/CMA first, then multigene HPE panels or exome sequencing; exome can increase diagnosis in previously negative cases (pqac-00000007) | test labels: karyotype, chromosomal microarray, multigene panel, exome sequencing | Review of HPE diagnostics | This is general HPE guidance, not a syndrome-specific practice guideline for CNOT1 |
| Supportive treatment | No disease-specific molecular therapy identified; management is supportive and organ-based, including **insulin replacement** for diabetes and **pancreatic enzyme replacement therapy** for exocrine insufficiency/pancreas agenesis, plus multidisciplinary HPE care (feeding, neurologic, endocrine, developmental support) (pqac-00000007, pqac-00000000) | MAXO labels: insulin therapy; pancreatic enzyme replacement therapy; supportive care | General pancreatic agenesis/NDM management; HPE review | Evidence comes largely from analogous pancreas agenesis/neonatal diabetes care rather than CNOT1-specific interventional studies |
| Prognosis | Prognosis is guarded because HPE has high mortality and universal neurodevelopmental burden in severe forms; reported syndrome outcomes range from termination of pregnancy/fetal demise to infant death or survival with developmental impairment (pqac-00000004, pqac-00000008) | HPO labels: global developmental delay; intellectual disability | Human case summaries; general HPE outcome literature | Long-term natural history for CNOT1 Arg535Cys syndrome is poorly defined because only a few cases are known |
| Evidence gaps | No disease-specific clinical trials were identified; protective factors, modifier genes, population prevalence, and validated biomarkers remain undefined for this ultra-rare syndrome (pqac-00000000, pqac-00000001) | label: evidence gap / not established | Database curation + literature synthesis | Many counseling points must rely on extrapolation from general HPE and pancreas agenesis literature rather than syndrome-specific data |


*Table: This table summarizes concise, ontology-oriented findings for Holoprosencephaly 12 with or without pancreatic agenesis, emphasizing the recurrent CNOT1 p.Arg535Cys syndrome, core phenotypes, mechanisms, diagnostics, and supportive care. It is designed to help map evidence into disease knowledge base fields while clearly marking limitations and extrapolations.*